Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin

British Journal of Clinical Pharmacology

Volumn 48, Issue 4, 1999, Pages 528-535

  Svensson, U S H ^a   Ashton, M ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b NONE

Author keywords

Artemisinin; CYP2B6; CYP3A4; Cytochrome P450; Metabolism

Indexed keywords

ARTEMISININ; COMPLEMENTARY DNA; CYTOCHROME P450; DRUG METABOLIZING ENZYME; ENZYME INHIBITOR; ISOENZYME; KETOCONAZOLE; METHOXSALEN; ORPHENADRINE; RECOMBINANT ENZYME; TROLEANDOMYCIN;

ARTICLE; CELL LINE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; LYMPHOBLASTOID CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS;

ANTIMALARIALS; ARTEMISININS; ARYL HYDROCARBON HYDROXYLASES; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; DRUG INTERACTIONS; HUMANS; ISOENZYMES; KETOCONAZOLE; METHOXSALEN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; ORPHENADRINE; OXIDOREDUCTASES, N-DEMETHYLATING; REGRESSION ANALYSIS; SESQUITERPENES; TIME FACTORS; TROLEANDOMYCIN;

EID: 0032853806     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00044.x     Document Type: Article

References (32)

1. 1 Klayman DL, Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985; 228: 1049-1055.
2. 2 Dien T, de Vries P, Khanh N, et al. Effect of food intake on pharmacokinetics of oral artemisinin in healthy vietnamese subjetcs. Antimicrob Agents Chemother 1997; 41: 1069-1072.
3. 3 Niu X, Ho L, Ren Z, Song Z. Metabolic fate of Qinghaosu in rats; a new TLC densitometric method for its determination in biological material. Eur J Drug Metab Pharmacokinet 1985; 10: 55-59.
4. 4 Lee I-K, Hufford C. Metabolism of antimalarial sesquiterpene lactones. Pharmacol Ther 1990; 48: 345-355.
5. 5 Ashton M, Sy ND, Gordi T, et al. Evidence for time-dependent artemisinin kinetics in adults with uncomplicated malaria. Pharm Pharmacol Lett 1996; 6: 127-130.
6. 6 Hassan Alin M, Ashton M, Kihamia CM, Mtey GJB, Björkman A. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans Roy Soc Trop Med Hyg 1996; 90: 61-65.
7. 7 Ashton M, Sy ND, Huong NV, et al. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 1998; 63: 482-493.
8. 8 Ashton M, Hai TN, Sy ND, et al. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos 1998; 26: 25-27.
9. 9 Sidhu JS, Ashton M, Huong NV, et al. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol 1998; 45: 347-354.
10. 10 Svensson USH, Ashton M, Hai TN, et al. Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 1998; 64: 160-167.
11. 11 Svensson USH, Sandström R, Carlborg Ö, Lennernäs H, Ashton M. High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement. Drug Metab Dispos 1999; 27: 227-232.
12. 12 Mäenpää J, Sigusch H, Raunio H, et al. Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem Pharmacol 1993; 45: 1035-1042.
13. 13 Heyn H, White RB, Stevens JC. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 1996; 24: 948-954.
14. 14 Reidy G, Mehta I, Murray M. Inhibition of oxidative drug metabolism by orphenadrine: In vitro and in vivo evidence for isozyme specific complexation of cytochrome P-450 and inhibition kinetics. Mol Pharmacol 1989; 35: 736 743.
15. 15 Baldwin SJ, Bloomer JC, Smith GJ, et al. Ketoconazole and sulphaphenazole as the respective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261-270.
16. 16 Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992; 6: 752-758.
17. 17 Newton DJ, Wang RW, Lu AYH. Cytochrome P 450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
18. 18 Edlund PO, Westerlund D, Carlqvist J, Bo-Liang W, Yunhua J. Determination of artesunate and dihydroartemisinine in plasma by liquid chromatography with post-column derivatization and UV detection. Acta Pharm Suec 1984; 21: 223-234.
19. 19 Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Belmont, CA. Wadsworth 1984.
20. 20 Jonsson EN, Karlsson MO. X-pose - an S-PLUS based population pharmacokinetic-pharmacodynamic model building aid for NONMEM. Comp Meth Prog Biomed 1998; 58: 51-64.
21. 21 Yamano S, Nhamburo PT, Aoyama T, et al. cDNA cloning and sequence and cDNA-directed expression of human P-450IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 1989; 28: 7340-7348.
22. 22 Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
23. 23 Grace JM, Aguilar AJ, Trotman KM, Brewer TG. Metabolism of β arteether to dihydroqinghaosu hy human liver microsomes and recombinant cytochrome P450. Drug Metab Disp 1998; 26: 313-317.
24. 24 Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991; 256: 1189-1194.
25. 25 Forrester LM, Henderson CJ, Glancey MJ, et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with metabolism of drugs and xenobiotics. Biochem J 1992; 281: 359-368.
26. 26 Bangchang KN, Karbwang J, Back DJ. Mefloquine metabolism by human liver microsomes. Biochem Pharmacol 1992; 43: 1957 1961.
27. 27 McManus ME, Burgess WM, Veronese ME, et al. Metabolism of 2-acetylaminofluorene and benzo (a) pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res 1990; 50: 3367-3376.
28. 28 Murray BP, Edwards RJ, Murray S, et al. Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis 1993; 14: 585 592.
29. 29 Verotta D. Building population pharmacokinetic-pharmacodynamic models using trees. In: COSTB1 medicine; European cooperation in the field of scientific, technical research. eds. Commission E, Belgium: European Communities 1997 17-24.
30. 30 Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
31. 31 Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducrs and autoinduction of oxazaphosphorines. Cancer Res 1997; 57: 1946 1954.
32. 32 Guo Z, Raeissi S, White RB, Stevens JC. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos 1997; 25: 390 393.